Sandeep K. Gupta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sandeep K. Gupta has a total of 118 co-authors. Here are the top co-authors by number of shared publications:
- Ikuo Hirano
Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
5 shared publications Joseph F. Fitzgerald
Division of Pediatric Gastroenterology/Hepatology/Nutrition Indiana University School of Medicine Indianapolis
5 shared publications- Alain M. Schoepfer
Farncombe Family Institute of Digestive Health Research, McMaster University, Hamilton, ON, Canada 4 Department of Visceral Surgery and Medicine, Gastroenterology, University of Bern/Inselspital, Switzerland
4 shared publications - Alex Straumann
Department of Gastroenterology and Hepatology University Hospital Zurich Zurich Switzerland
4 shared publications Jean P. Molleston
4 shared publicationsMargaret H. Collins
4 shared publications
Latest Publications
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
Sa1123 - Histologic Characterization of a Multi-Center Retrospective Cohort of Patients with Eosinophilic Gastrointestinal Disorders
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
Sa1123 - Histologic Characterization of a Multi-Center Retrospective Cohort of Patients with Eosinophilic Gastrointestinal Disorders
- 25 March 2017
- Published by Springer Nature
- p. 723-737
Eosinophilic Esophagitis (North America)
- 1 May 2016
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 83 (5) , AB301
Sa2060 Inadequate Bowel Preparation in Pediatric Colonoscopy - Prospective Study of Potential Causes
- 1 May 2016
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 83 (5) , AB301
Sa2060 Inadequate Bowel Preparation in Pediatric Colonoscopy - Prospective Study of Potential Causes
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S663-S664
Mo1186 Caregiver-Assessed EoE Activity in Children Between 3-9 Years of Age Poorly Correlates With Physician Global Assessment, Endoscopic or Histologic Activity
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S663-S664
Mo1186 Caregiver-Assessed EoE Activity in Children Between 3-9 Years of Age Poorly Correlates With Physician Global Assessment, Endoscopic or Histologic Activity
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S663
Mo1185 Substantial Variability in Biopsy Practice Patterns Among Gastroenterologists for Suspected Eosinophilic Gastrointestinal Disorders (EGID)
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S663
Mo1185 Substantial Variability in Biopsy Practice Patterns Among Gastroenterologists for Suspected Eosinophilic Gastrointestinal Disorders (EGID)
- 1 January 2015
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 13 (1) , 66-76.e3
Efficacy and Safety of Oral Budesonide Suspension in Pediatric Patients With Eosinophilic Esophagitis
- 1 January 2015
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 13 (1) , 66-76.e3
Efficacy and Safety of Oral Budesonide Suspension in Pediatric Patients With Eosinophilic Esophagitis
- 1 December 2011
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 53 (6) , 651-658
Exploring Potential Noninvasive Biomarkers in Eosinophilic Esophagitis in Children
Background and Aims: Eosinophilic esophagitis (EE) continues to present clinical challenges, including a need for noninvasive tools to manage the disease. To identify a marker able to assess disease status in lieu of repeated endoscopies, we examined 3 noninvasive biomarkers, serum interleukin (IL)‐5, serum eosinophil‐derived neurotoxin (EDN), and stool EDN, and examined possible correlations of these with disease phenotype and activity (symptoms and histology) in a longitudinal study of children with EE.Subjects and Methods: Children with EE were studied for up to 24 weeks (12 weeks on 1 of 2 corticosteroid therapies and 12 weeks off therapy). Twenty children with normal esophagogastroduodenoscopies with biopsies were enrolled as controls. Serum IL‐5, serum EDN, and stool EDN were measured at weeks 0, 4, 12, 18, and 24 in children with EE, and at baseline alone for controls. Primary and secondary statistical analyses (excluding and including outlier values of the biomarkers, respectively) were performed.Results: Sixty subjects with EE (46 [75%] boys, mean age 7.5 ± 4.4 years) and 20 normal controls (10 [50%] boys, mean age 6.7 ± 4.1 years) were included. Significant changes in serum EDN (significant decrease from baseline to week 4, and then rebound from week 4 to week 12) occurred. Serum EDN levels were stable after week 12. Serum IL‐5 and stool EDN levels in subjects with EE were not statistically different from those of the control subjects when each time point for the cases was compared with the controls’ 1‐time measurement.Conclusions: Serum EDN levels were significantly higher in subjects with EE than in controls, and the results suggest a possible role, after additional future studies, for serum EDN in establishing EE diagnosis, assessing response to therapy, and/or monitoring for relapse or quiescence.
- 1 December 2011
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 53 (6) , 651-658
Exploring Potential Noninvasive Biomarkers in Eosinophilic Esophagitis in Children
Background and Aims: Eosinophilic esophagitis (EE) continues to present clinical challenges, including a need for noninvasive tools to manage the disease. To identify a marker able to assess disease status in lieu of repeated endoscopies, we examined 3 noninvasive biomarkers, serum interleukin (IL)‐5, serum eosinophil‐derived neurotoxin (EDN), and stool EDN, and examined possible correlations of these with disease phenotype and activity (symptoms and histology) in a longitudinal study of children with EE.Subjects and Methods: Children with EE were studied for up to 24 weeks (12 weeks on 1 of 2 corticosteroid therapies and 12 weeks off therapy). Twenty children with normal esophagogastroduodenoscopies with biopsies were enrolled as controls. Serum IL‐5, serum EDN, and stool EDN were measured at weeks 0, 4, 12, 18, and 24 in children with EE, and at baseline alone for controls. Primary and secondary statistical analyses (excluding and including outlier values of the biomarkers, respectively) were performed.Results: Sixty subjects with EE (46 [75%] boys, mean age 7.5 ± 4.4 years) and 20 normal controls (10 [50%] boys, mean age 6.7 ± 4.1 years) were included. Significant changes in serum EDN (significant decrease from baseline to week 4, and then rebound from week 4 to week 12) occurred. Serum EDN levels were stable after week 12. Serum IL‐5 and stool EDN levels in subjects with EE were not statistically different from those of the control subjects when each time point for the cases was compared with the controls’ 1‐time measurement.Conclusions: Serum EDN levels were significantly higher in subjects with EE than in controls, and the results suggest a possible role, after additional future studies, for serum EDN in establishing EE diagnosis, assessing response to therapy, and/or monitoring for relapse or quiescence.